NDAORALTABLETPriority Review
Approved
Jun 2025
Lifecycle
Launch
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
YEZTUGO (lenacapavir sodium) is an oral small-molecule antiviral approved by FDA in June 2025 for HIV treatment. It represents a novel mechanistic approach to HIV therapy delivered in tablet form. The specific indication and mechanism of action are under review pending full prescribing information release.
Growth12.1 years to LOE
Early-stage launch phase with zero competitive pressure creates significant opportunity for brand-building and market capture in a differentiated HIV therapy segment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Gilead Sciences is hiring 1 role related to this product
Worked on YEZTUGO at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.